Group 1 - The core viewpoint of the news highlights the financial performance and trading activity of Kemei Diagnostics, indicating a decline in revenue and net profit for the first quarter of 2025 compared to the previous year [2] - As of August 26, Kemei Diagnostics experienced a financing net buy of -2.23 million yuan, with a total financing and securities balance of 206 million yuan, which is 5.86% of its market capitalization [1] - The company has a significant reliance on its LiCA series products, which account for 92.04% of its main business revenue [1] Group 2 - As of March 31, the number of shareholders for Kemei Diagnostics increased by 14.69% to 11,000, while the average circulating shares per person decreased by 12.81% to 36,384 shares [2] - For the first quarter of 2025, Kemei Diagnostics reported an operating income of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit attributable to shareholders of 14.54 million yuan, down 62.12% year-on-year [2] - The company has distributed a total of 306 million yuan in dividends since its A-share listing, with 238 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a decline in revenue and profit in the latest quarter [1] - Kemei Diagnostics' stock closed at 8.32 yuan, down 4.26%, with a rolling PE ratio of 32.33 times and a total market capitalization of 3.337 billion yuan [1] - The company ranks 66th in the medical device industry, which has an average PE ratio of 55.76 times and a median of 39.14 times [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company obtained 64 new domestic and international authorized patents during the reporting period, showcasing its innovation capability and technical reserves [1] Group 3 - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3001 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5428 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

8月7日，科美诊断今日收盘8.62元，上涨1.65%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到33.50倍，总市值34.58亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.79倍，行业中值37.86倍，科美诊断排 名第68位。 股东方面，截至2025年3月31日，科美诊断股东户数11024户，较上次增加1412户，户均持股市值35.28 万元，户均持股数量2.76万股。 科美诊断技术股份有限公司的主营业务是临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售。 公司的主要产品是LiCA系列产品、CC系列产品。报告期内，公司新获得境内外授权专利64项，其中境 内发明专利33项，境内实用新型专利20项，外观设计专利11项。展现出公司持续壮大的创新能力和技术 储备。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断33.5027.212.4234.58亿行业平均 54.7951.294.8011 ...

最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断33.4227.152.4134.50亿行业平均 54.2450.504.73115.46亿行业中值37.9236.662.7954.21亿1九安医疗10.9911.110.87185.40亿2英科医疗 15.6216.841.39246.81亿3新华医疗16.0314.861.31102.77亿4山东药玻16.0716.121.85152.03亿5振德医疗 16.4215.471.0459.61亿6奥美医疗16.7916.461.7360.67亿7康德莱17.8017.811.4738.35亿8九强生物 17.8316.582.1888.30亿9维力医疗18.0519.292.2742.32亿10奥泰生物18.2519.241.4758.21亿11鱼跃医疗 19.9119.532.69352.67亿12安图生物20.2419.322.60230.80亿 来源：金融界 8月5日，科 ...

8月4日，科美诊断今日收盘8.76元，上涨3.18%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到34.04倍，创367天以来新低，总市值35.14亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，科美诊断排 名第68位。 股东方面，截至2025年3月31日，科美诊断股东户数11024户，较上次增加1412户，户均持股市值35.28 万元，户均持股数量2.76万股。 科美诊断技术股份有限公司的主营业务是临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售。 公司的主要产品是LiCA系列产品、CC系列产品。报告期内，公司新获得境内外授权专利64项，其中境 内发明专利33项，境内实用新型专利20项，外观设计专利11项。展现出公司持续壮大的创新能力和技术 储备。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断34.0427.652.4635.14亿行业平均 54.325 ...

Group 1 - The core viewpoint of the news is that Kemei Diagnostics has experienced a significant increase in stock price, reaching 8.49 yuan, up 6.66%, with a rolling PE ratio of 32.99, marking a new low in 113 days [1] - The total market capitalization of Kemei Diagnostics is 3.405 billion yuan, while the average PE ratio in the medical device industry is 53.65, and the median is 37.22, placing Kemei Diagnostics at the 68th position in the industry ranking [1] - As of March 31, 2025, Kemei Diagnostics has 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Kemei Diagnostics specializes in the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with major products including the LiCA series and CC series [1] - The company has obtained 64 new domestic and international authorized patents during the reporting period, including 33 domestic invention patents, 20 domestic utility model patents, and 11 design patents, indicating strong innovation capability and technical reserves [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a significant decline in revenue and net profit in the latest quarterly report [1][2] - Kemei Diagnostics' stock closed at 7.99 yuan, with a rolling PE ratio of 31.05, marking a new low in 90 days, and a total market capitalization of 3.205 billion yuan [1] - The company ranks 63rd in the medical device industry, which has an average PE ratio of 55.28 and a median of 38.06 [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company has obtained 64 new domestic and international patents during the reporting period, showcasing its growing innovation capability and technological reserves [1] Group 3 - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics, which has a current PE ratio of 30.46, significantly lower than the industry average of 54.56 [1][2] - Kemei Diagnostics has a total market capitalization of 3.145 billion yuan, ranking 62nd in the medical device industry based on PE ratio [1][2] - The company has seen an increase in shareholder numbers, with 11,024 shareholders as of March 31, 2025, an increase of 1,412 from the previous count [1] Group 2 - Kemei Diagnostics specializes in the research, development, production, and sales of clinical immunochemistry diagnostic reagents and instruments, with key products including the LiCA and CC series [1] - The company has demonstrated strong innovation capabilities, acquiring 64 new domestic and international patents during the reporting period, including 33 domestic invention patents [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported a revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12% [1]

Core Viewpoint - The company, Kemei Diagnostics, has shown a decline in revenue and net profit in the latest quarterly report, while its stock price has reached a new low in terms of rolling P/E ratio compared to the industry average [1][2]. Company Summary - Kemei Diagnostics closed at 7.73 yuan, up 2.11%, with a rolling P/E ratio of 30.04, marking a 77-day low and a total market capitalization of 3.101 billion yuan [1]. - The company operates in the clinical immunochemistry and chemiluminescence diagnostic testing sector, focusing on the research, production, and sales of diagnostic reagents and instruments [1]. - The main products include the LiCA series and CC series [1]. - In the reporting period, Kemei Diagnostics obtained 64 new domestic and international patents, including 33 domestic invention patents, 20 utility model patents, and 11 design patents, indicating strong innovation capability and technical reserves [1]. Financial Performance - For Q1 2025, Kemei Diagnostics reported revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]. Industry Summary - The average P/E ratio for the medical device industry is 52.34, with a median of 36.99, placing Kemei Diagnostics at the 64th position within the industry [2]. - The average P/B ratio for the industry is 4.60, while Kemei Diagnostics has a P/B ratio of 2.17 [2]. - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics in the medical device industry, indicating a lower PE ratio compared to industry averages [1][2] - Kemei Diagnostics closed at 7.11 yuan, with a PE ratio of 27.63, while the industry average PE is 48.89 [1][2] - The company's total market capitalization is 2.852 billion yuan, ranking 64th in the industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, nine institutions hold shares in Kemei Diagnostics, with a total holding of 206.2876 million shares valued at 1.537 billion yuan [1] - The main business of Kemei Diagnostics includes the research, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company has obtained 64 new domestic and international patents during the reporting period, showcasing its innovation capabilities [1] Group 3 - In the latest performance report for the first quarter of 2025, Kemei Diagnostics reported revenue of 81.3001 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5428 million yuan, down 62.12% [1] - The gross profit margin for the company stands at 66.88% [1]